Dr Liz Dallimore on the exciting times ahead for Argenica Therapeutics as they fast track Phase 2
MAKING MONEY MATTER: Biotech companies have not been top of investors minds recently but I was excited to speak with Dr Liz Dallimore of Argenica Therapeutics (ASX:AGN) who are moving from Phase 1 to Phase 2 trials. Since we last spoke there has been a steady increase in the share price as they work on a drug to reduce brain damage after strokes as well as other brain injuries.TIME STAMPS:00:00 intro02:00 Background to Argenica Therapeutics (asx:AGN) and what sets them apart04:30 Phase 1 and Phase 2 trials and the outcomes from the trials06:50 The competition08:30 The recent placement and use of funds going forward12:00 The importance of the FDA approval and the market in the USA14:30 Timelines for the phase 2 trials and any challenges?18:00 Progress with the FDA21:00 Current valuation and milestones ahead and future partners23:30 The other applications for the company going forward26:30 Three reasons to sit up and take notice right now
- Forums
- ASX - By Stock
- AGN Media thread
Dr Liz Dallimore on the exciting times ahead for Argenica...
Featured News
Add AGN (ASX) to my watchlist
|
|||||
Last
75.5¢ |
Change
-0.028(3.51%) |
Mkt cap ! $93.39M |
Open | High | Low | Value | Volume |
78.0¢ | 79.5¢ | 75.5¢ | $118.1K | 154.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1824 | 75.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
79.5¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1824 | 0.755 |
4 | 35485 | 0.750 |
1 | 10000 | 0.745 |
3 | 16270 | 0.740 |
3 | 18999 | 0.730 |
Price($) | Vol. | No. |
---|---|---|
0.795 | 10000 | 1 |
0.800 | 5000 | 1 |
0.845 | 1851 | 1 |
0.880 | 5000 | 1 |
0.895 | 10000 | 1 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
AGN (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online